[1] WANG W，JIANG B，SUN H，et al. Prevalence，

incidence，and mortality of stroke in China：results

from a nationwide population-based survey of 480

687 adults[J]. Circulation，2017，135（8）：759-771.

[2] MACREZ R，ALI C，TOUTIRAIS O，et al. Stroke

and the immune system：from pathophysiology to

new therapeutic strategies[J]. Lancet Neurol，2011，

10（5）：471-480.

[3] SHI K，TIAN D C，LI Z G，et al. Global brain

inflammation in stroke[J]. Lancet Neurol，2019，18

（11）：1058-1066.

[4] ELTZSCHIG H K，CARMELIET P. Hypoxia and

inflammation[J]. N Engl J Med，2011，364（7）：656-

665.

[5] YILMAZ G，GRANGER D N. Leukocyte

recruitment and ischemic brain injury[J].

Neuromolecular Med，2010，12（2）：193-204.

[6] ENGELHARDT B，SOROKIN L. The blood-brain

and the blood-cerebrospinal fluid barriers：function

and dysfunction[J]. Semin Immunopathol，2009，31

（4）：497-511.

[7] FU Y，LIU Q，ANRATHER J，et al. Immune

interventions in stroke[J]. Nat Rev Neurol，2015，11

（9）：524-535.

[8] KONSMAN J P，DRUKARCH B，VAN DAM A

M. （Peri）vascular production and action of proinflammatory

cytokines in brain pathology[J]. Clin

Sci（Lond），2007，112（1）：1-25.

[9] MATZINGER P. Friendly and dangerous signals：is

the tissue in control?[J]. Nat Immunol，2007，8（1）：

11-13.

[10] BUNE L T，THANING P，JOHANSSON P I，et

al. Effects of nucleotides and nucleosides on

coagulation[J]. Blood Coagul Fibrinolysis，2010，21

（5）：436-441.

[11] BURNSTOCK G. Purinergic signalling and

disorders of the central nervous system[J]. Nat Rev

Drug Discov，2008，7（7）：575-590.

[12] BOURS M J，SWENNEN E L，DI VIRGILIO F，

et al. Adenosine 5'-triphosphate and adenosine as

endogenous signaling molecules in immunity and

inflammation[J]. Pharmacol Ther，2006，112（2）：

358-404.

[13] HOEK R M，RUULS S R，MURPHY C A，et al.

Down-regulation of the macrophage lineage through

interaction with OX2（CD200）[J]. Science，2000，

290（5497）：1768-1771.

[14] PETROVIC-DJERGOVIC D，GOONEWARDENA

S N，PINSKY D J. Inflammatory Disequilibrium in

Stroke[J]. Circ Res，2016，119（1）：142-158.

[15] DENES A，MCCOLL B W，LEOW-DYKE S F，et

al. Experimental stroke-induced changes in the bone

marrow reveal complex regulation of leukocyte

responses[J]. J Cereb Blood Flow Metab，2011，31

（4）：1036-1050.

[16] LIU Q，JIN W N，LIU Y，et al. Brain ischemia

suppresses immunity in the periphery and brain via

different neurogenic innervations[J]. Immunity，2017，

46（3）：474-487.

[17] WESTENDORP W F，NEDERKOORN P

J，VERMEIJ J D，et al. Post-stroke infection：a

systematic review and meta-analysis[J/OL]. BMC

Neurol，2011，11：110. https：//doi.org/10.1186/1471-

2377-11-110.

[18] KWAN J，PICKERING R M，KUNKEL D，et al.

Impact of stroke-associated infection on long-term

survival：a cohort study[J]. J Neurol Neurosurg

Psychiatry，2013，84（3）：297-304.

[19] PRASS K，MEISEL C，HOFLICH C，et al. Strokeinduced

immunodeficiency promotes spontaneous

bacterial infections and is mediated by sympathetic

activation reversal by poststroke T helper cell type

1-like immunostimulation[J]. J Exp Med，2003，198

（5）：725-736.

[20] PRICE C J，WANG D，MENON D K，et al. Intrinsic

activated microglia map to the peri-infarct zone in the subacute phase of ischemic stroke[J]. Stroke，

2006，37（7）：1749-1753.

[21] MIJAJLOVIC M D，PAVLOVIC A，BRAININ

M，et al. Post-stroke dementia - a comprehensive

review[J]. BMC Med，2017，15（1）：11.

[22] LEES K R，BLUHMKI E，VON KUMMER R，et

al. Time to treatment with intravenous alteplase

and outcome in stroke：an updated pooled analysis

of ECASS，ATLANTIS，NINDS，and EPITHET

trials[J]. Lancet，2010，375（9727）：1695-1703.

[23] WEI Y，YEMISCI M，KIM H H，et al. Fingolimod

provides long-term protection in rodent models of

cerebral ischemia[J]. Ann Neurol，2011，69（1）：

119-129.

[24] TIAN D C，SHI K，ZHU Z，et al. Fingolimod

enhances the efficacy of delayed alteplase

administration in acute ischemic stroke by promoting

anterograde reperfusion and retrograde collateral

flow[J]. Ann Neurol，2018，84（5）：717-728.

[25] KEVIN N，SHETH M D. Efficacy，safety and

tolerability of BAF312 compared to placebo in

patients with intracerebral hemorrhage（ICH）

[EB/OL]. （2017-11-09）[2019-11-04]. https：//

clinicaltrials.gov/ct2/show/NCT03338998.

[26] KAPOOR R，HO P R，CAMPBELL N，et al. Effect

of natalizumab on disease progression in secondary

progressive multiple sclerosis（ASCEND）：a phase 3，

randomised，double-blind，placebo-controlled trial

with an open-label extension[J]. Lancet Neurol，2018，

17（5）：405-415.

[27] ELKINS J，VELTKAMP R，MONTANER J，et al.

Safety and efficacy of natalizumab in patients with

acute ischaemic stroke（ACTION）：a randomised，

placebo-controlled，double-blind phase 2 trial[J].

Lancet Neurol，2017，16（3）：217-226.

[28] EMSLEY H C，SMITH C J，GEORGIOU R F，et

al. A randomised phase Ⅱ study of interleukin-1

receptor antagonist in acute stroke patients[J]. J

Neurol Neurosurg Psychiatry，2005，76（10）：1366-

1372.

[29] ZHANG R L，CHOPP M，LI Y，et al. Anti-ICAM-1

antibody reduces ischemic cell damage after

transient middle cerebral artery occlusion in the

rat[J]. Neurology，1994，44（9）：1747-1751.

[30] ENLIMOMAB ACUTE STROKE TRIAL I. Use

of anti-ICAM-1 therapy in ischemic stroke：results

of the Enlimomab Acute Stroke Trial[J]. Neurology，

2001，57（8）：1428-1434.

[31] SHETH K N，ELM J J，MOLYNEAUX B J，et

al. Safety and efficacy of intravenous glyburide on

brain swelling after large hemispheric infarction

(GAMES-RP): a randomised，double-blind，

placebo-controlled phase 2 trial[J]. Lancet Neurol，

2016，15（11）：1160-1169.